Deal Statistics Quarterly, Q1 2004
Statistical review compiled from our Strategic Transactions database including financings by type (IPO, private placement etc.); financings by sector (surgical equipment, implantable devices, etc.); alliances by therapeutic category (cardiovascular, orthopedic, etc.); alliances by industry segment (biomaterials, monitoring equipment, etc. ); for three separate industries: medical devices, in vitro diagnostics, and pharmaceuticals/biotechnology.
You may also be interested in...
The press around the size of Jazz Pharmaceuticals' $250 million private financing has obscured the whole point: the company and the financing represent a fundamentally different business model for biopharmaceutical investing and companies: betting on product concepts--not products and not technology.
The Yamanouchi/Fujisawa acquisition may be the most important transaction to have occured in Japan in decades--or will be if it goes through. One key element: the deal ends important merger options for mid-size Japanese companies, who had more or less closed off transaction possibilities with Western companies at least partly in the hope of being able to do an intra-Japan deal. Now the Western firms have decided to build their own Japanese infrastructure, leaving the mid-sized firms without the strategic flexibility they once thought they had.
Abbott's TheraSense acquisition clearly helps resurrect its flagging MediSense diabetes device business. It may also signal a new aggressiveness for Abbott as it emerges from the long shadow of an FDA consent decree.